58 products were found matching "K04322"!

Description: Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. This response is mediated via a G-protein...

Selective leukotriene LTD4 receptor antagonist, Potent MRP1 inhibitor, Antinociceptive.

MN-001 is an anti-inflammatory agent. In vivo, MN-001 (10, 30, and 50 mg/kg) reduces the frequency of bladder voids, increases the intercontractile interval, and decreases the number of non-voiding contractions in a rat model of bladder hyperactivity induced by ovalbumin-induced mast cell stimulation.Formal Name:...

LY171883 is a selective, potent, orally active antagonist of the leukotriene D4 receptor. Dissociation constants (KB) for LY171883 on guinea pig ileum and parenchyma are 0.07 and 0.34 µM, respectively. LY171883 is an inhibitor of phosphodiesterase obtained from human polymorphonuclear leukocytes (IC50 of 22.6 µM)...

LY171883 is a PDE inhibitor and a selective, potent inhibitor of the leukotriene D4 receptor. Also, LY171883 binds to the PPAR nuclear receptor at 50-100 µM and induces adipogenesis in cultured NIH3T3 fibroblasts.

A cysteinyl leukotriene receptor antagonist with anti-inflammatory effects. In rat colitis it has been shown to increase prostaglandin E(2) production and decrease the cyclogenase-2 protein expression.

VEGF-C/Nrp2 inhibitor. Leukotriene receptor antagonist.

Montelukast-d6 (sodium salt) is intended for use as an internal standard for the quantification of montelukast (sodium salt) (Cay-10008318) by GC- or LC-MS. Montelukast is a cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50 = 4.9 nM in HEK293 cell membranes expressing the human receptor). It is selective...

Dihydro montelukast is a potential impurity found in commercial montelukast preparations. Montelukast (sodium salt) (Cay-10008318) is a potent and selective cysteinyl leukotriene 1 (CysLT1) receptor antagonist. Formulations containing montelukast are used for the treatment of asthma as well as for the symptoms...

Pranlukast-d4 is intended for use as an internal standard for the quantification of pranlukast (Cay-10008319) by GC- or LC-MS. Pranlukast is an orally bioavailable cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50s = 4.3-7.2 nM in radioligand binding assays). It is selective for the CysLT1 receptor over the...

Protein function: Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. This response is mediated via a...